Source: http://hc-sc.gc.ca/ahc-asc/activit/atip-aiprp/requests-demandes/_2014/req-dem-05-eng.php
Timestamp: 2017-10-21 19:30:54
Document Index: 558435159

Matched Legal Cases: ['art 150', 'art 1', 'art 26', 'art 5', 'art 148', 'art 23', 'art 135', 'art 14', 'art 17', 'art 85', 'art 13', 'art 27', 'art 118', 'art 21', 'art 5', 'art 56', 'art 153', 'art 150', 'art 9', 'art 2', 'art 1', 'art 1', 'art 2', 'art 2', 'art 41', 'art 60', 'art 92', 'art 1', 'art 7', 'art 2', 'art 249', 'art 24', 'art 10', 'art 2', 'art 2', 'art 12', 'art 75', 'art 30', 'art 35', 'art 4', 'art 8', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 4', 'art 23', 'art 1', 'art 1', 'art 1', 'art 12', 'art 1', 'art 5', 'art 12', 'art 1', 'art 3', 'art 187', 'art 4', 'art 4', 'art 10', 'art 4', 'art 1', 'art 2', 'art 2', 'art 1', 'art 1']

Access to Information Requests Completed - May 2014 - Health Canada
Access to Information Requests Completed - May 2014
A-2011-01071 Documents referring to the process by which the next phase of Federal Tobacco Control Strategy will be developed and implemented. (Jan 1, 2011 to Nov 9, 2011). Disclosed in part 150
A-2011-01351 Documents related to the risk assessment, risk management and international review/assessments of Vanadium Pentoxide (V20S). (Sep 1, 2011 to Jan 1, 2012). Disclosed in part 1,187
A-2012-01641 Adverse Reaction Report (AER) for Aspirin. Report numbers: 000450592, 000462730. Disclosed in part 26
A-2013-00524 Adverse Reaction Report (AER) for Calcitonin. Report number: 000509656. Disclosed in part 5
A-2013-00625 Copies of all Question Period notes, memoranda and briefing notes referring to generic medication supplier Ranbaxy. (Jan 1, 2013 to Aug. 28, 2013). All disclosed 3
A-2013-00740 All Adverse Reaction Reports from physicians prescribing drugs under the Special Access Programme. (Jan 1, 2012 to Sep 26, 2013). Disclosed in part 148
A-2013-00954 List of reports, studies and briefing notes related to acetaminophen health concerns. (Jan 1, 2000 to Nov 7, 2013). All disclosed 17
A-2013-01068 Documents relating to samples submitted to the Toronto lab by the Owen Sound Police and the Royal Canadian Mounted Police that turned out to be that turned out to be methylenedioxypyrovalerone (MDPV) in whole or part. (Apr 1, 2011 to Nov 30, 2012). All disclosed 146
A-2013-01073 Information regarding NITOMAN, Drug Identification Number (DIN) 02199270. Disclosed in part 23
A-2013-01076 Briefing book prepared for the new health minister appointed on July 15, 2013 that refers to OxyContin, Oxycodone, or OxyNeo, and any briefing materials prepared subsequently for the minister or deputy minister. Disclosed in part 135
A-2013-01097 Information regarding the medical device LASER PROBES, License number 80942 by OMEGA LASER SYSTEMS LIMITED. Disclosed in part 14
A-2013-01098 Information regarding the medical device ENOBIO, License number 90344 by NEUROELECTRICS BARCELONA S.L. Disclosed in part 17
A-2013-01099 Information regarding the medical device ALPHA-STIM AID, License number 88147 by ELECTROMEDICAL PRODUCTS INTERNATIONAL, INC. Disclosed in part 85
A-2013-01100 Information regarding the medical device Alpha-Stim, License number 61332 by ELECTROMEDICAL PRODUCTS INTERNATIONAL INC. Disclosed in part 13
A-2013-01195 A copy of the following document: Title: Potential health hazards from shale gas exploration and exploitation Date: May 4, 2012. All disclosed 187
A-2013-01196 Documents regarding report #1 of the Natural Health Products Program Advisory Committee (NHP-PAC). Disclosed in part 27
A-2013-01233 Documents relating to the 2011 risk assessment report for Yasmin 21 and Yasmin 28, Drug Identification Number (DIN) 02261723 and 02261731. Disclosed in part 118
A-2013-01257 Lists of companies which hold production and/or distribution establishment licences for medical supplies in Canada. (Jan. 1, 2004 to Jan. 28, 2014). No records exist 0
A-2013-01263 List of companies which produce and/or distribute medical supplies in Canada whose establishment licences has been suspended. (Jan. 1, 2004 to Jan 23, 2014). No records exist 0
A-2013-01331 Adverse Reaction Report (AER). Report number: 000456111. Disclosed in part 21
A-2013-01355 Adverse Reaction Report (AER) for BIAXIN. Report numbers: 000537924, 000543616. Disclosed in part 5
A-2013-01365 Information regarding Listerine Whitening Plus Restoring, Natural Product Number (NPN) 80011245. Disclosed in part 56
A-2013-01383 Notice of Compliance with conditions Qualifying Notice (NOC/c-QN) for the following products: Rescriptor (delavirdine), Viramune (nevirapine), Niastase (recombinant factor VIIa), Activase (alteplase), Ziagen (abacavir), Relenza (zanamivir), Rilutek (riluzole), Agenerase (amprenavir). No records exist 0
A-2013-01388 All reports made to Health Canada by the Ministry of Health and/or the University of BC's Faculty of Medicine for the Expansion and Distribution of the International Medical Graduates BC Program for Underserved Communities in British Columbia (BC). Disclosed in part 153
A-2013-01389 All reports made to Health Canada by the Ministry of Health and/or the University of BC Faculty of Medicine for the Expansion and Distribution of the International Medical Graduates BC Program for Underserved Communities in British Columbia (BC). (Feb 27, 2009 to Feb 26, 2014). Disclosed in part 150
A-2013-01413 Document reflecting the number of surveys conducted by firms or consultants to identify confidential, secret or top secret information or document leaks made to journalists or media groups by public servants or employees. (Jan 1, 2005 to Feb 26, 2014). All disclosed 2
A-2013-01415 Adverse Reaction Report (AER) for Humira. Report numbers: 000539905, 000540936, 000541041, 000542877. Disclosed in part 9
A-2013-01431 Documents regarding notification of health impairment and/or health effects by RES Canada Construction, Renewable Energy Systems, Enbridge Green Energy, Green Energy for the Talbot Windfarm / Spence Windfarm. (Jan 1, 2009 to Nov 30, 2010). All disclosed 243
A-2013-01432 Health and safety workplace inspection reports for 875 Heron Road, Ottawa, Ontario. October 2002. All disclosed 16
A-2013-01446 Letter issued prior to January 30, 2006 from Therapeutic Products Directorate to Pharmascience Inc. certifying that the examination of PMS-Azithromycin (Azithromycin) 250 mg tablets was complete. Disclosed in part 2
A-2013-01447 Letter issued prior to January 30, 2006 from Therapeutic Products Directorate to Ratiopharm Inc. certifying that the examination of Ratio-Azithromycin tablets was complete. No records exist 0
A-2013-01449 Letter issued prior to November 2, 2005 from Therapeutic Products Directorate to Rhoxalpharma Inc. certifying that the examination of Sandoz-Azithromycln (Azithromycin Monohydrate Hemiethanolate) 250 mg tablets was complete. Disclosed in part 1
A-2013-01450 Letter issued prior to August 10, 2006 from Therapeutic Products Directorate to Pharmel Inc. certifying that the examination of Pharmel's Phi-Azithromycin (Azithromycin Monohydrate Hemlethanolate) 250 mg tablets was complete. Disclosed in part 1
A-2013-01468 Letter issued prior to November 8, 2012 from Therapeutic Products Directorate to Pharmascience Inc. certifying that the examination of PMS-Sildenafil (Sildenafil Citrate) tablets was complete. Disclosed in part 2
A-2013-01469 Letter issued prior to November 08, 2012 from Therapeutic Products Directorate to Dominion Pharmacal certifying that the examination of DOM-Sildenafil tablets was complete. No records exist 0
A-2013-01473 Letter issued prior to November 08, 2012 from Therapeutic Products Directorate to Sandoz Canada Inc. certifying that the examination of Sandoz Sildenafil (Sildenafil Citrate) mg tablets was complete. Disclosed in part 2
A-2013-01479 Update on Reduced-Risk Pesticides in Canada (RR2008-01) published by Pest Management Regulatory Agency. All disclosed 129
A-2013-01481 Adverse Reaction Report (AER) for Fludara. Report numbers: 000542415, E2B_00016363. Disclosed in part 41
A-2013-01484 Adverse Reaction Report (AER) for Fludara. Report number: E2B_00011228. Disclosed in part 60
A-2013-01485 Adverse Reaction Report (AER) for Fludara. Report number: E2B_00011423. Disclosed in part 92
A-2013-01487 Adverse Reaction Report (AER) for SPIRIVA. Report number: 000505533. Disclosed in part 1
A-2013-01509 Documents regarding notification of health impairment and/or health effects by Renewable Energy Systems and Enbridge for the Talbot Wind Project. (Jan 1, 2009 to Mar 18, 2014). All disclosed 243
A-2013-01511 Adverse Reaction Report (AER) for Busulfan. Report number: 000551252. Disclosed in part 7
A-2013-01512 Adverse Reaction Report (AER) for Busulfan. Report number: 000551654. Disclosed in part 2
A-2013-01518 Information regarding RAN-ACETAMINOPHEN 8 HOUR, Drug Identification Number (DIN) 02283433 by Ranbaxy Pharmaceuticals Canada Inc. Disclosed in part 249
A-2013-01519 Information regarding Buckley'S Mixture, Natural Product Number (NPN) 02239538 by The Buckley's Company. Disclosed in part 24
A-2013-01526 Documents in regards to follow up monitoring for K1 (Kingsbridge 1) that was to help provide more data for a more informed future environmental assessment reviews. All disclosed 9
A-2013-01552 The number of licenses to produce cannabis (marihuana) that have been issued under the Marihuana Medical Access Program to recipients within various cities of Ontario (Jan 1, 2012 to Mar 22, 2014). All disclosed 1
A-2013-01557 Number of Special Access Programme releases for the drug Buccolam (midazolam hydrochloride). (Jan 1, 2012 to Dec 31, 2013). No records exist 0
A-2014-00008 An overview of contracts awarded including price, duration, scope, and successful bidder on the Real Property procurement stream during fiscal year 2013-2014l Disclosed in part 10
A-2014-00009 Number of licenced medical marihuana grow operation (and name of licenced companies) in British Columbia. (Apr 1, 2013 to Apr 1, 2014). Disclosed in part 2
A-2014-00011 Letter issued prior to November 04, 2013 from Therapeutic Products Directorate to Taro Pharmaceuticals Inc. certifying that the examination of Taro-Latanoprost was complete. No records exist 0
A-2014-00012 Letter issued prior to August 19, 2011 from Therapeutic Products Directorate to Apotex Inc. certifying that the examination of Apo-Latanoprost ophthalmic solution was complete. Disclosed in part 2
A-2014-00014 A listing of the Access to Information requests submitted to Health Canada. (March 1, 2014 to March 31, 2014). Disclosed in part 12
A-2014-00025 Documents with the rationale for the revised code, mentioned on page 24 of "A Review of Safety Code 6 (2013): Health Canada's Safety Limits for Exposure to Radiofrequency Fields: An Expert Panel Report" All disclosed 46
A-2014-00037 All bills, receipts, invoices, expense claims or expense reports, for travel, hospitality or incidental expenses submitted to Health Canada, by or on behalf of the Parliamentary Secretary to the Minister of Health. (Sep 1, 2013 to Apr 10, 2014). Disclosed in part 75
A-2014-00038 Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during. (Dec 1, 2013 to Mar 31, 2014). All disclosed 14
A-2014-00044 Information regarding complaints for Xerion Formula; Mozi-Q, Natural Product Number (NPN) 80031902. (Jan 1, 2010 to Apr 11, 2014). No records exist 0
A-2014-00061 Controlled Drugs and Substances Act (CDSA) Section 56 authorizations and applications in support of CDSA Section 56 authorizations in relation to the distribution of medical cannabis through a pharmacy. No records exist 0
A-2014-00071 Documents related to the attendance of Health Canada employees at the 5th International Meeting on Wind Turbine Noise in Denver in August 2013. (Aug 1, 2012 to Apr 15, 2014). Disclosed in part 30
A-2014-00072 Documents regarding inaccurate citations contained in the papers entitled Trading off Human Health: Wind Turbine Noise and Government and/or Audit Report: Literature Reviews on Wind Turbine Noise and Health published in the proceedings of the 5th International Meeting on Wind Turbine Noise in Denver in August 2013. No records exist 0
A-2014-00074 Documents which analyses and/or discusses and/or refers to any of the following power point presentations presented at the 5th International Meeting on Wind Turbine Noise in Denver in August 2013: Literature reviews on wind turbine noise and Trading off human health: Wind turbine noise and government policy. No records exist 0
A-2014-00075 Documents which analyses and/or discusses and/or refers to the references:
Industrial wind turbines and adverse health effects Can J Rural Med 2014;19(1)
Adverse health effects of industrial wind turbines Can Fam Physician 2013; 59: 473-475 and Can Fam Physician 2013; 59: 921-924.
(May 1, 2013, to Apr 15, 2014). No records exist 0
A-2014-00078 Information regarding ACETYLSALICYLIC ACID 80 MG CHEWABLE TABLETS, Drug Identification Number (DIN) 02269139 by JAMP PHARMA CORPORATION. Disclosed in part 35
A-2014-00083 Adverse Reaction Report (AER) for Tubersol. Report number: 000566261. Disclosed in part 4
A-2014-00084 Adverse Reaction Report (AER) for Vaxigrip. Report number: 000574178. Disclosed in part 8
A-2014-00085 Adverse Reaction Report (AER) for Vaxigrip. Report number: 000571884. Disclosed in part 1
A-2014-00086 Adverse Reaction Report (AER) for Tubersol. Report number: 000579467. Disclosed in part 1
A-2014-00087 Adverse Reaction Report (AER) for Tubersol. Report number: 000569096. Disclosed in part 1
A-2014-00088 Adverse Reaction Report (AER) for Tubersol. Report number: 000575917. Disclosed in part 1
A-2014-00089 Adverse Reaction Report (AER) for Tubersol. Report number: 000559407. Disclosed in part 1
A-2014-00092 Adverse Reaction Report (AER) for Effient. Report number: 000573554. Disclosed in part 1
A-2014-00095 Documents regarding the following:
Posti BD (1989), Community Health Assessment, Grassy Narrow Band Final Report.
Department of National Health and Welfare Canada (1973), Task Force on Organic Mercury in the Environment Grassy Narrows and White Dog, Final Report.
All disclosed 51
A-2014-00105 Adverse Reaction Report (AER) for ACTOS. Report numbers: 000506189, 000541123, 000554882. Disclosed in part 4
A-2014-00106 Adverse Reaction Report (AER) for DEXILANT. Report numbers: 000493351, 000499116, 000504643, 000509759, 000510389, 000526545, 000533036, 000536191, 000541542, 000544089, 000551400, 000552387, 000555897, 000564566, 000568457, 000573913, 00057516. Disclosed in part 23
A-2014-00107 Adverse Reaction Report (AER) for ULORIC. Report number: 000552565. Disclosed in part 1
A-2014-00111 Adverse Reaction Report (AER) for Humulin. Report number: 000562383. Disclosed in part 1
A-2014-00112 Adverse Reaction Report (AER) for Prozac. Report number: 000576315. Disclosed in part 1
A-2014-00113 Adverse Reaction Report (AER) for Straterra. Report numbers: 000565520, 000576263, 000577814. Disclosed in part 12
A-2014-00115 Adverse Reaction Report (AER) for Zyprexa. Report number: 000565964. Disclosed in part 1
A-2014-00124 Documents relating to the nuclear device Nuclear 5010 that is certified by the Canadian Nuclear Safety Commission. No records exist 0
A-2014-00134 Adverse Reaction Report (AER) for OMNARIS. Report numbers: 000537485, 000571892. Disclosed in part 5
A-2014-00135 Adverse Reaction Report (AER) for FERAHEME. Report numbers: 000559452, 000559909, 000559912, 000564174, 000568149, 000568151, 000568153, 000568154, 000568155, 000568157, 000571835. Disclosed in part 12
A-2014-00136 Adverse Reaction Report (AER) for PIOGLITAZONE. Report number: 000489382. Disclosed in part 1
A-2014-00138 Adverse Reaction Report (AER) for DAXAS. Report numbers: 000530221, 000568316, 000573245. Disclosed in part 3
A-2014-00146 All communications regarding discussions about the eye and safety code 6. (Jan 1, 2012 to Apr 29, 2014). Disclosed in part 187
A-2014-00147 Adverse Reaction Report (AER) for Thymoglobulin. Report number: 000537834. Disclosed in part 4
A-2014-00148 Adverse Reaction Report (AER) for Thymoglobulin. Report number: 000537830. Disclosed in part 4
A-2014-00150 A listing of the Access to Information requests submitted to Health Canada. (Feb 1, 2014 to Feb 28, 2014). Disclosed in part 10
A-2014-00161 Adverse Reaction Report (AER) for Lantus. Report number: 000570451. All disclosed 3
Names of all tobacco product manufacturers who have submitted the following reports required under the Tobacco Reporting Regulations:
Addressing tobacco constituents
Addressing mainstream smoke emission testing
Addressing sidestream smoke emission testing
Addressing cigarette toxicity testing
(Jan 1 2012 to Feb 28, 2014). All disclosed 3
A-2014-00168 Various information regarding reports, studies, toxicology and clinical tests relating to hydrofluosilicic acid in Canadian tap water No records exist 0
A-2014-00177 Adverse Reaction Report (AER) for Celexa. Report numbers: 000559367, 000567554. Disclosed in part 4
A-2014-00186 Adverse Reaction Report (AER) for Pradaxa. Report number: 000560031. Disclosed in part 1
A-2014-00191 Adverse Reaction Report (AER) for Lantus. Report number: 000563334. Disclosed in part 2
A-2014-00200 Adverse Reaction Report (AER) for Plavix. Report number: 000566165. Disclosed in part 2
A-2014-00206 Most current Product Monograph for the product STERILE WATER FOR INJECTION USP, DIN 02349760 by Laboratories Sterigen Inc. No records exist 0
A-2014-00224 Adverse Reaction Report (AER) for Eloxatin. Report number: 000555027. Disclosed in part 1
A-2014-00225 Adverse Reaction Report (AER) for Micardis. Report number: 000453486. Disclosed in part 1